6 O
ADVERSE O
REACTIONS O
The O
following O
have O
been O
observed O
with O
BENLYSTA O
and O
are O
discussed O
in O
detail O
in O
the O
Warnings O
and O
Precautions O
section O
: O
* O
Mortality B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Serious O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
, O
including O
Anaphylaxis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Depression B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Malignancy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

EXCERPT O
: O
* O
Common O
adverse O
reactions O
( O
> O
=5 O
% O
) O
: O
nausea O
, O
diarrhea O
, O
pyrexia O
, O
nasopharyngitis O
, O
bronchitis O
, O
insomnia O
, O
pain O
in O
extremity O
, O
depression O
, O
migraine O
, O
pharyngitis O
, O
and O
injection O
site O
reactions O
( O
subcutaneous O
administration O
) O
. O

( O
6.1 O
, O
6.2 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-877-423-6597 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
with O
Intravenous O
Administration O
The O
data O
described O
below O
reflect O
exposure O
to O
BENLYSTA O
administered O
intravenously O
plus O
standard O
therapy O
compared O
with O
placebo O
plus O
standard O
therapy O
in O
2,133 O
patients O
in O
3 O
controlled O
trials O
. O

Patients O
received O
BENLYSTA O
plus O
standard O
therapy O
at O
doses O
of O
1 O
mg/kg O
( O
n O
= O
673 O
) O
, O
4 O
mg/kg O
( O
n O
= O
111 O
; O
Trial O
1 O
only O
) O
, O
or O
10 O
mg/kg O
( O
n O
= O
674 O
) O
, O
or O
placebo O
plus O
standard O
therapy O
( O
n O
= O
675 O
) O
intravenously O
over O
a O
1-hour O
period O
on O
Days O
0 O
, O
14 O
, O
28 O
, O
and O
then O
every O
28 O
days O
. O

In O
2 O
of O
the O
trials O
( O
Trial O
1 O
and O
Trial O
3 O
) O
, O
treatment O
was O
given O
for O
48 O
weeks O
, O
while O
in O
the O
other O
trial O
( O
Trial O
2 O
) O
treatment O
was O
given O
for O
72 O
weeks O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Because O
there O
was O
no O
apparent O
dose-related O
increase O
in O
the O
majority O
of O
adverse O
events O
observed O
with O
BENLYSTA O
, O
the O
safety O
data O
summarized O
below O
are O
presented O
for O
the O
3 O
intravenous O
doses O
pooled O
, O
unless O
otherwise O
indicated O
; O
the O
adverse O
reaction O
table O
displays O
the O
results O
for O
the O
recommended O
intravenous O
dose O
of O
10 O
mg/kg O
compared O
with O
placebo O
. O

The O
population O
had O
a O
mean O
age O
of O
39 O
years O
( O
range O
: O
18 O
to O
75 O
) O
, O
94 O
% O
were O
female O
, O
and O
52 O
% O
were O
white O
. O

In O
these O
trials O
, O
93 O
% O
of O
patients O
treated O
with O
BENLYSTA O
plus O
standard O
therapy O
reported O
an O
adverse O
event O
compared O
with O
92 O
% O
treated O
with O
placebo O
plus O
standard O
therapy O
. O

The O
most O
common O
serious O
adverse O
events O
were O
serious O
infections B-OSE_Labeled_AE
( O
6.0 O
% O
and O
5.2 O
% O
in O
the O
groups O
receiving O
BENLYSTA O
and O
placebo O
plus O
standard O
therapy O
, O
respectively O
) O
, O
some O
of O
which O
were O
fatal B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

The O
most O
commonly O
reported O
adverse O
events O
, O
occurring O
in O
> O
=5 O
% O
of O
patients O
in O
clinical O
trials O
were O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
and O
pharyngitis B-OSE_Labeled_AE
. O

The O
proportion O
of O
patients O
who O
discontinued O
treatment O
due O
to O
any O
adverse O
reaction O
during O
the O
controlled O
clinical O
trials O
was O
6.2 O
% O
for O
patients O
receiving O
BENLYSTA O
plus O
standard O
therapy O
and O
7.1 O
% O
for O
patients O
receiving O
placebo O
plus O
standard O
therapy O
. O

The O
most O
common O
adverse O
reactions O
resulting O
in O
discontinuation O
of O
treatment O
( O
> O
=1 O
% O
of O
patients O
receiving O
BENLYSTA O
or O
placebo O
) O
were O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
1.6 O
% O
BENLYSTA O
and O
0.9 O
% O
placebo O
) O
, O
lupus B-NonOSE_AE
nephritis I-NonOSE_AE
( O
0.7 O
% O
BENLYSTA O
and O
1.2 O
% O
placebo O
) O
, O
and O
infections B-NonOSE_AE
( O
0.7 O
% O
BENLYSTA O
and O
1.0 O
% O
placebo O
) O
. O

Table O
1 O
lists O
adverse O
reactions O
, O
regardless O
of O
causality O
, O
occurring O
in O
at O
least O
3 O
% O
of O
patients O
with O
SLE B-Not_AE_Candidate
who O
received O
BENLYSTA O
10 O
mg/kg O
plus O
standard O
therapy O
and O
at O
an O
incidence O
at O
least O
1 O
% O
greater O
than O
that O
observed O
with O
placebo O
plus O
standard O
therapy O
in O
the O
3 O
controlled O
studies O
. O

Table O
1 O
. O

Incidence O
of O
Adverse O
Reactions O
Occurring O
in O
at O
Least O
3 O
% O
of O
Patients O
Treated O
with O
BENLYSTA O
10 O
mg/kg O
plus O
Standard O
Therapy O
and O
at O
Least O
1 O
% O
More O
Frequently O
than O
in O
Patients O
Receiving O
Placebo O
plus O
Standard O
Therapy O
Preferred O
Term O
BENLYSTA O
10 O
mg/kg O
+ O
Standard O
Therapy O
( O
n O
= O
674 O
) O
% O
Placebo O
+ O
Standard O
Therapy O
( O
n O
= O
675 O
) O
% O
Nausea B-OSE_Labeled_AE
15 O
12 O
Diarrhea B-OSE_Labeled_AE
12 O
9 O
Pyrexia B-OSE_Labeled_AE
10 O
8 O
Nasopharyngitis B-OSE_Labeled_AE
9 O
7 O
Bronchitis B-OSE_Labeled_AE
9 O
5 O
Insomnia B-OSE_Labeled_AE
7 O
5 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
6 O
4 O
Depression B-OSE_Labeled_AE
5 O
4 O
Migraine B-OSE_Labeled_AE
5 O
4 O
Pharyngitis B-OSE_Labeled_AE
5 O
3 O
Cystitis B-OSE_Labeled_AE
4 O
3 O
Leukopenia B-OSE_Labeled_AE
4 O
2 O
Gastroenteritis B-OSE_Labeled_AE
viral I-OSE_Labeled_AE
3 O
1 O
6.2 O
Clinical O
Trials O
Experience O
with O
Subcutaneous O
Administration O
The O
data O
described O
below O
reflect O
exposure O
to O
BENLYSTA O
administered O
subcutaneously O
plus O
standard O
therapy O
compared O
with O
placebo O
plus O
standard O
therapy O
in O
836 O
patients O
in O
a O
controlled O
trial O
( O
Trial O
4 O
) O
. O

In O
addition O
to O
standard O
therapy O
, O
patients O
received O
BENLYSTA O
200 O
mg O
( O
n O
= O
556 O
) O
or O
placebo O
( O
n O
= O
280 O
) O
( O
2:1 O
randomization O
) O
once O
weekly O
for O
up O
to O
52 O
weeks O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
. O

The O
overall O
population O
had O
a O
mean O
age O
of O
39 O
years O
( O
range O
: O
18 O
to O
77 O
) O
, O
94 O
% O
were O
female O
, O
and O
60 O
% O
were O
white O
. O

In O
the O
trial O
, O
81 O
% O
of O
patients O
treated O
with O
BENLYSTA O
plus O
standard O
therapy O
reported O
an O
adverse O
event O
compared O
with O
84 O
% O
treated O
with O
placebo O
plus O
standard O
therapy O
. O

The O
proportion O
of O
patients O
who O
discontinued O
treatment O
due O
to O
any O
adverse O
reaction O
during O
the O
controlled O
clinical O
trial O
was O
7.2 O
% O
of O
patients O
receiving O
BENLYSTA O
plus O
standard O
therapy O
and O
8.9 O
% O
of O
patients O
receiving O
placebo O
plus O
standard O
therapy O
. O

The O
safety O
profile O
observed O
for O
BENLYSTA O
administered O
subcutaneously O
plus O
standard O
therapy O
was O
consistent O
with O
the O
known O
safety O
profile O
of O
BENLYSTA O
administered O
intravenously O
plus O
standard O
therapy O
, O
with O
the O
exception O
of O
local O
injection B-NonOSE_AE
site I-NonOSE_AE
reactions I-NonOSE_AE
. O

Injection O
Site O
Reactions O
In O
the O
clinical O
study O
for O
BENLYSTA O
administered O
subcutaneously O
, O
the O
frequency O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
6.1 O
% O
( O
34/556 O
) O
for O
patients O
receiving O
BENLYSTA O
plus O
standard O
therapy O
and O
2.5 O
% O
( O
7/280 O
) O
for O
patients O
receiving O
placebo O
plus O
standard O
therapy O
. O

These O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
most O
commonly O
pain O
, O
erythema O
, O
hematoma O
, O
pruritus O
, O
and O
induration O
) O
were O
mild O
to O
moderate O
in O
severity O
. O

The O
majority O
( O
94 O
% O
) O
did O
not O
necessitate O
discontinuation O
of O
treatment O
. O

6.3 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
BENLYSTA O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Fatal B-NonOSE_AE
anaphylaxis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

6.4 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
belimumab I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
in O
other O
studies O
or O
to O
other O
products O
may O
be O
misleading O
. O

In O
Trials O
2 O
and O
3 O
( O
intravenous O
dosing O
) O
, O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
belimumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected O
in O
4 O
of O
563 O
( O
0.7 O
% O
) O
patients O
receiving O
BENLYSTA O
10 O
mg/kg O
and O
in O
27 O
of O
559 O
( O
4.8 O
% O
) O
patients O
receiving O
BENLYSTA O
1 O
mg/kg O
. O

The O
reported O
frequency O
for O
the O
group O
receiving O
10 O
mg/kg O
may O
underestimate O
the O
actual O
frequency O
due O
to O
lower O
assay O
sensitivity O
in O
the O
presence O
of O
high O
drug O
concentrations O
. O

Neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected I-OSE_Labeled_AE
in O
3 O
patients O
receiving O
BENLYSTA O
1 O
mg/kg O
. O

Three O
patients O
with O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
belimumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
experienced O
mild O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
of O
nausea B-OSE_Labeled_AE
, O
erythematous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
eyelid B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
dyspnea B-OSE_Labeled_AE
; O
none O
of O
the O
reactions O
was O
life-threatening O
. O

In O
Trial O
4 O
( O
subcutaneous O
dosing O
) O
, O
there O
was O
no O
formation O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
belimumab I-NonOSE_AE
antibodies I-NonOSE_AE
in O
556 O
patients O
receiving O
BENLYSTA O
200 O
mg O
during O
the O
52-week O
placebo-controlled O
period O
. O

The O
clinical O
relevance O
of O
the O
presence O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
belimumab I-NonOSE_AE
antibodies I-NonOSE_AE
is O
not O
known O
. O

The O
data O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
belimumab I-NonOSE_AE
in O
specific O
assays O
. O

